Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) (DBCOND0138147)

Identifiers

Synonyms

Head and Neck Cancer Metastatic / Metastatic Squamous Cell Carcinoma of the Head or Neck / Metastatic Squamous cell carcinoma of head and neck / Metastatic Head and Neck Cancer / Metastatic Squamous Cell Carcinoma of the Head and Neck / Metastatic Head-and-neck Squamous-cell Carcinoma / Metastatic Head and Neck Squamous Cell Carcinoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cetuximab	An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.	Epidermal growth factor receptortarget Low affinity immunoglobulin gamma Fc region receptor III-Btarget Complement C1q subcomponent subunit Atarget Complement C1q subcomponent subunit Btarget Complement C1q subcomponent subunit Ctarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget High affinity immunoglobulin gamma Fc receptor Itarget Low affinity immunoglobulin gamma Fc region receptor II-atarget
Docetaxel	A taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 10transporter Cytochrome P450 1B1enzyme Microtubule-associated protein 2target Microtubule-associated protein 4target Microtubule-associated protein tautarget Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 7transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Nuclear receptor subfamily 1 group I member 2target
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03878979	Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN	Nivolumab	treatment	2	completed
NCT03993353	Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer	Pembrolizumab Tadalafil	treatment	2	recruiting
NCT03265080	A Study of ADXS-NEO Expressing Personalized Tumor Antigens	Pembrolizumab	treatment	1	terminated
NCT02474368	Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck	Cisplatin	treatment	1	active_not_recruiting
NCT05582590	Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers	Cyclophosphamide Fludarabine	treatment	1	not_yet_recruiting
NCT03652233	Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Afatinib Nivolumab	treatment	1	withdrawn
NCT05980000	Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma	Pembrolizumab Ramucirumab	treatment	2	recruiting
NCT05259319	Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)	Atezolizumab Tiragolumab	treatment	1	recruiting
NCT06239220	PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC	CD-16 NK-92 cells Cetuximab Nogapendekin alfa	treatment	2	recruiting
NCT03146338	Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)	No drug interventions	prevention	Not Available	unknown_status
NCT05091190	Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers	No drug interventions	other	Not Available	recruiting
NCT05057247	Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC	Docetaxel Duvelisib	treatment	2	active_not_recruiting
NCT04534205	A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1	Pembrolizumab	treatment	2	recruiting
NCT04969861	BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)	Bempegaldesleukin Pembrolizumab	treatment	2 / 3	terminated
NCT00088907	Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer	Docetaxel Gefitinib	treatment	3	terminated
NCT01620242	A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes	Cabazitaxel	treatment	2	completed
NCT03991741	Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors	Lifileucel	treatment	1	recruiting
NCT03937141	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer	ADU-S100 Pembrolizumab	treatment	2	terminated
NCT03323424	Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers	No drug interventions	treatment	2	withdrawn
NCT04260126	Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC	Pembrolizumab	treatment	2	active_not_recruiting
NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	Carboplatin Cetuximab Cisplatin Fluorouracil Pembrolizumab	treatment	3	completed
NCT04902027	A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers	Mitoxantrone	treatment	1	completed
NCT05271604	A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Cetuximab Evalstotug Ozuriftamab vedotin Pembrolizumab	treatment	2	recruiting
NCT06064877	A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma	Cetuximab Ficlatuzumab	treatment	3	recruiting
NCT04831320	Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor	Nivolumab Paclitaxel	treatment	2	active_not_recruiting
NCT04454489	Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition	Pembrolizumab	treatment	2	suspended
NCT04305795	An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	Cemiplimab Cetuximab sarotalocan Pembrolizumab	treatment	1 / 2	active_not_recruiting
NCT04375384	Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer	Cetuximab	treatment	2	recruiting
NCT02119559	Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma	No drug interventions	Not Available	Not Available	unknown_status
NCT05047094	A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC	Pembrolizumab	treatment	Not Available	recruiting
NCT02449681	Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin	Tarloxotinib	treatment	2	terminated
NCT03522584	Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Durvalumab Tremelimumab	treatment	1 / 2	terminated
NCT03875053	Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer	No drug interventions	diagnostic	Not Available	withdrawn
NCT05156970	Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC	Camrelizumab Carboplatin Cisplatin Docetaxel Rivoceranib	treatment	2	recruiting
NCT03813836	Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC	Pembrolizumab	treatment	2	recruiting
NCT05172258	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	Ipatasertib Pembrolizumab	treatment	2	recruiting
NCT06211335	Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma	Losartan Pembrolizumab	treatment	1	recruiting
NCT00494182	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	Carboplatin Paclitaxel Sorafenib	treatment	2	active_not_recruiting
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Pembrolizumab Sonidegib	treatment	1	recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT05721755	Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck	Carboplatin Chloride ion Cisplatin Fluorouracil Paclitaxel Pembrolizumab Platinum	treatment	3	recruiting
NCT04862650	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Carboplatin Cemiplimab Paclitaxel	treatment	2	recruiting
NCT04643379	Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	Carboplatin Olaparib Pembrolizumab	treatment	2	active_not_recruiting
NCT03590054	Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies	Abexinostat Pembrolizumab	treatment	1	completed
NCT06265285	Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	Nivolumab	health_services_research	2	recruiting
NCT01602315	A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Alpelisib Cetuximab	treatment	1 / 2	terminated
NCT05063552	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	Atezolizumab Bevacizumab Carboplatin Cetuximab Chloride ion Cisplatin Docetaxel Platinum	treatment	2 / 3	recruiting
NCT03575949	Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer	No drug interventions	diagnostic	Not Available	completed
NCT01468896	Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	Cetuximab Edodekin alfa Interleukin-12 human recombinant Natural Killer Cell	treatment	1 / 2	active_not_recruiting
NCT05747625	(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma	Panitumumab	diagnostic	1	recruiting
NCT03868020	Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease	No drug interventions	diagnostic	0	completed
NCT03823131	Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat	Epacadostat Pembrolizumab Tavokinogene telseplasmid	treatment	2	terminated
NCT05359692	INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Ragifilimab Retifanlimab	treatment	2	withdrawn
NCT04862455	NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer	Hafnium oxide Pembrolizumab	treatment	2	recruiting